Cargando…

PERS&O (PERsistent Sitagliptin treatment & Outcomes): observational retrospective study on cardiovascular risk evolution in patients with type 2 diabetes on persistent sitagliptin treatment

OBJECTIVES: The UK Prospective Diabetes Study (UKPDS) Risk Engine (RE) provides the best risk estimates available for people with type 2 diabetes (T2D), so it was applied to patients on persistent sitagliptin treatment. DESIGN: A ‘real-world’ retrospective, observational, single-center study. SETTIN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buonaiuto, Giulia, De Mori, Valentina, Braus, Alessandra, Balini, Annalisa, Berzi, Denise, Carpinteri, Rita, Forloni, Franco, Meregalli, Giancarla, Ronco, Gian Luca, Bossi, Antonio C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Cardiovascular and Metabolic Risk
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947782/ https://www.ncbi.nlm.nih.gov/pubmed/27486519 http://dx.doi.org/10.1136/bmjdrc-2016-000216

Ejemplares similares

PERsistent Sitagliptin treatment & Outcomes (PERS&O 2.0) study, long-term results: a real-world observation on DPP4-inhibitor effectiveness
por: Bossi, Antonio Carlo, et al.
Publicado: (2020)

Sitagliptin for the prevention of stress hyperglycemia in patients without diabetes undergoing coronary artery bypass graft (CABG) surgery
por: Cardona, Saumeth, et al.
Publicado: (2019)

Breakfast skipping is associated with persistently increased arterial stiffness in patients with type 2 diabetes
por: Mita, Tomoya, et al.
Publicado: (2020)

Unresponsive Intractable Chronic Headache With Sitagliptin
por: Zaghloul, Ahmed, et al.
Publicado: (2018)

A Rare Case Report of Sitagliptin-Induced Angioedema
por: Sharma, Nava R, et al.
Publicado: (2022)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

Is sitagliptin effective for the treatment of COVID-19?
por: Memiş, Hasan, et al.
Publicado: (2022)

Sitagliptin-induced Pancreatitis: Chronic Use Would Not Spare You the Complication
por: Alkayali, Talal, et al.
Publicado: (2020)

A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment
por: Mariam, Arshiya, et al.
Publicado: (2021)

Impact of pharmacological treatment of diabetes mellitus on dementia risk: systematic review and meta-analysis
por: McMillan, Jacqueline M, et al.
Publicado: (2018)

Insulin treatment in patients with diabetes mellitus and heart failure in the era of new antidiabetic medications
por: Staszewsky, Lidia, et al.
Publicado: (2022)

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial
por: Zobel, Emilie H, et al.
Publicado: (2021)

Noncardiac Pulmonary Edema induced by Sitagliptin Treatment
por: Belice, Tahir, et al.
Publicado: (2014)

Sitagliptin-induced hemolysis
por: Bekur, Ragini, et al.
Publicado: (2010)

Sitagliptin-Associated Angioedema
por: Gosmanov, Aidar R., et al.
Publicado: (2012)

Lipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk
por: Quek, Ruben G W, et al.
Publicado: (2015)

Use of an electronic health record to identify prevalent and incident cardiovascular disease in type 2 diabetes according to treatment strategy
por: Korytkowski, Mary T, et al.
Publicado: (2016)

Use of a Metabolic Syndrome Severity Z Score to Track Risk During Treatment of Prediabetes: An Analysis of the Diabetes Prevention Program
por: DeBoer, Mark D., et al.
Publicado: (2018)

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis
por: Rossing, Peter, et al.
Publicado: (2022)

Acute Liver Injury Induced by Sitagliptin: Report of Two Cases and Review of Literature
por: Shahbaz, Amir, et al.
Publicado: (2018)

Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
por: Longato, Enrico, et al.
Publicado: (2020)

Heart Rate Variability and Cardiac Autonomic Dysfunction: Prevalence, Risk Factors, and Relationship to Arterial Stiffness in the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study
por: Shah, Amy S., et al.
Publicado: (2019)

Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
por: Scott, Russell, et al.
Publicado: (2009)

Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes: A prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT)
por: Ruggenenti, Piero, et al.
Publicado: (2008)

Design of and rationale for the Japan Diabetes Optimal Integrated Treatment study for 3 major risk factors of cardiovascular diseases (J-DOIT3): a multicenter, open-label, randomized, parallel-group trial
por: Ueki, Kohjiro, et al.
Publicado: (2016)

Blood Pressure and Fasting Plasma Glucose Rather Than Metabolic Syndrome Predict Coronary Artery Calcium Progression: The Rancho Bernardo Study
por: Kramer, Caroline K., et al.
Publicado: (2009)

Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?
por: Cho, Yong Kyun
Publicado: (2018)

Effect of sitagliptin on proteinuria in patients with type 2 diabetes – A renoprotective effect of sitagliptin
por: Narimani, Rouhollah, et al.
Publicado: (2021)

Six-Year Complete Remission of Type-1 Diabetes Mellitus in an Adult Treated With Sitagliptin
por: Benido Silva, Vânia, et al.
Publicado: (2023)

Fixed drug eruption to sitagliptin
por: Gupta, Mrinal, et al.
Publicado: (2015)

Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease
por: Sayari, Saba, et al.
Publicado: (2018)

Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
por: Charytan, David M, et al.
Publicado: (2023)

New combination treatments in the management of diabetes: focus on sitagliptin – metformin
por: Green, Jennifer, et al.
Publicado: (2008)

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
por: Miller, Shannon A, et al.
Publicado: (2009)

Randomized Clinical Trial on Efficacy of Empagliflozin Versus Sitagliptin, In Addition to Metformin in Type 2 Diabetic Patients
por: Mubashir, Muaz, et al.
Publicado: (2022)

OR05-6 The Effect of the GLP1R Variant rs6923761 on Post-Prandial Glucose Levels during Treatment with Sitagliptin
por: Mashayekhi, Mona, et al.
Publicado: (2019)

Sitagliptin: Is It Effective in Routine Clinical Practice?
por: Mohan Dallumal, Rita, et al.
Publicado: (2015)

Pancreatic Safety of Sitagliptin in the TECOS Study
por: Buse, John B., et al.
Publicado: (2017)

Prevalence of the Metabolic Syndrome Among a Racially/Ethnically Diverse Group of U.S. Eighth-Grade Adolescents and Associations With Fasting Insulin and Homeostasis Model Assessment of Insulin Resistance Levels
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_i8cji4d2p39gp3otq7dgvb27fa